Literature DB >> 9825479

The relevance of somatostatin receptors in thyroid neoplasia.

H Ahlman1, L E Tisell, B Wängberg, M Fjälling, E Forssell-Aronsson, L Kölby, O Nilsson.   

Abstract

111In-octreotide scintigraphy in patients with persistent medullary thyroid carcinoma (MTC) visualized tumors in about half of the surgically explored sites. Tumor visualization correlated with rapid tumor growth and large tumor volume as judged from calcitonin levels. The 111In concentration ratio between tumor (T) and blood (B) in surgically excised lymph node metastases of MTC showed a large variation, with low values for microscopic and high values for macroscopic metastases in individual patients. Three cases of MTC, Hürthle cell adenoma and papillary thyroid cancer are reported with preoperative scintigraphy, T/B ratios and Northern analyses of the surgical biopsies. Visualization of tumors was possible in the absence of sstr2 (the high affinity receptor for octreotide) with the exception of microscopic tumor growth. T/B values in the patient with Hürthle cell adenoma were similar to those found in the contralateral thyroid lobe with goitre. The relatively high uptake of 111In in benign thyroid conditions probably limits the use of octreotide scintigraphy in the diagnosis of primary tumors. The technique has certain advantages over radioiodine scintigraphy after the surgical treatment of thyroid tumors: no need for withdrawal of thyroxin substitution; a possibility to diagnose metastases of tumors that do not concentrate radioiodine (MTC, Hürthle cell cancer); and complementary information about metastatic sites of non-medullary thyroid cancer (papillary and follicular tumors).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9825479      PMCID: PMC2589271     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  26 in total

Review 1.  Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer.

Authors:  H R Maxon; H S Smith
Journal:  Endocrinol Metab Clin North Am       Date:  1990-09       Impact factor: 4.741

2.  Tumor uptake as a function of tumor mass: a mathematic model.

Authors:  L E Williams; R B Duda; R T Proffitt; B G Beatty; J D Beatty; J Y Wong; J E Shively; R J Paxton
Journal:  J Nucl Med       Date:  1988-01       Impact factor: 10.057

3.  Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group.

Authors:  U Bergholm; H O Adami; R Bergström; M Bäckdahl; G Akerström
Journal:  Acta Chir Scand       Date:  1990-01

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma.

Authors:  A Miyauchi; T Onishi; S Morimoto; S Takai; F Matsuzuka; K Kuma; M Maeda; Y Kumahara
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

6.  Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma.

Authors:  L E Tisell; G Hansson; S Jansson; H Salander
Journal:  Surgery       Date:  1986-01       Impact factor: 3.982

7.  Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging.

Authors:  S A Wells; S B Baylin; D S Gann; R E Farrell; W G Dilley; S H Preissig; W M Linehan; C W Cooper
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

8.  Total thyroidectomy for Hürthle cell neoplasm of the thyroid.

Authors:  S R Gundry; R E Burney; N W Thompson; R Lloyd
Journal:  Arch Surg       Date:  1983-05

9.  New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid.

Authors:  H J Buhr; T Lehnert; F Raue
Journal:  Eur J Surg Oncol       Date:  1990-08       Impact factor: 4.424

10.  Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells.

Authors:  S Tsuzaki; A C Moses
Journal:  Endocrinology       Date:  1990-06       Impact factor: 4.736

View more
  3 in total

1.  Somatostatin receptor expression in thyroid disease.

Authors:  Helen Atkinson; James A England; Amy Rafferty; Vim Jesudason; Karen Bedford; Laszlo Karsai; Stephen L Atkin
Journal:  Int J Exp Pathol       Date:  2013-06       Impact factor: 1.925

2.  99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.

Authors:  Michael Gabriel; Franz Froehlich; Clemens Decristoforo; Christian Ensinger; Eveline Donnemiller; Elisabeth von Guggenberg; Dirk Heute; Roy Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-19       Impact factor: 9.236

3.  Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels.

Authors:  Ajit S Shinto; K K Kamaleshwaran; Madhav Mallia; Aruna Korde; Grace Samuel; Sharmila Banerjee; Pavanasam Velayutham; Suresh Damodharan; Madhu Sairam
Journal:  World J Nucl Med       Date:  2015 May-Aug
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.